Organization
Hangzhou Sumgen Biotech
6 clinical trials
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Characteristics of SG301 SC Injection in Single-dose Healthy Subjects and Multiple-dose Systemic Lupus Erythematosus (SLE) SubjectsStatus: Recruiting, Estimated PCD: 2025-05-19
Clinical trial
A Phase Ia/Ib, First-in-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG2501 in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma.Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-28
Clinical trial
A Phase 1 Study of SG301 in Subjects With Hematological MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase I Clinical Study to Evaluate the Safety Tolerability and Preliminary Efficacy of SG2918 in Subjects With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2025-12-28
Clinical trial
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.Status: Recruiting, Estimated PCD: 2025-02-28